# Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm

> **NCT00908869** · PHASE1 · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 30 (actual)

## Conditions studied

- Advanced Neoplasm

## Interventions

- **DRUG:** Vinorelbine, Cyclophosphamide and Interferon alpha 2b

## Key facts

- **NCT ID:** NCT00908869
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-05
- **Final completion:** 2011-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00908869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00908869, "Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00908869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*